PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF-TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)

Patients who have metastatic RCC who are not eligible for surgery will all receive initial doses of Nivolumab and Ipilimumab. Following this, patients will be randomized to either receive more Nivolumab or Nivolumab with Cabozantinib to complete their treatment.

Principal Investigator(s)
Jianqing Lin, MD
Contact Phone Number
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

19 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.